Pfizer’s former Oncology Vice President, David Roth M.D., took on the post of senior vice president, clinical development and medical affairs with Infinity Pharmaceuticals Inc. (Nasdaq: INFI) of Cambridge.

Roth, who brings two decades of hematology and oncology R&D experience to his new position, will build and oversee Infinity’s clinical development and clinical operations as well as the company’s medical affairs functions. He will report to Infinity’s Chief Medical Officer Pedro Santabarbara, M.D., Ph.D. Prior to his leadership role with Pfizer, Roth held the post of assistant vice president, clinical research and development and global therapeutic area director of hematology with Wyeth Pharmaceuticals. Roth possesses a Bachelor of Science degree from the Massachusetts Institute of Technology and a M.D. from Harvard Medical School in the Harvard-M.I.T. Division of Health Sciences and Technology where he remains on the Affiliated Faculty.

Massachusetts Biotechnology Council board member and co-founder and former Semprus BioSciences CEO, David Lucchino was appointed to the board of directors of Pittsburgh, Penn.-based Lipella Pharmaceuticals Inc. Prior to co-founding Semprus with Massachusetts Institute of Technology’s Institute Professor, Robert S. Langer, Sc.D., Lucchino served as a senior associate at Boston-based Polaris Venture Partners, a $3 billion venture capital fund. In addition to his Mass Biotechnology Council position, Lucchino is a Multiple Myeloma Research Foundation board member, a trustee of Mt. Auburn Hospital in Cambridge, and a member of the audit committee for CareGroup, the parent organization of Mt. Auburn, Beth Israel Deaconess Medical Center and The New England Baptist Hospital.

Related links:

Industries:

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.